RCS - Faron Pharma. Oy - Presentation at J.P. Morgan Healthcare Conference

Faron Pharmaceuticals OyAnnouncement

03/01/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240103:nRSC4335Ya&default-theme=true

RNS Number : 4335Y  Faron Pharmaceuticals Oy  03 January 2024

Faron Pharmaceuticals Oy

("Faron" or "Company")

 

Faron Pharmaceuticals to Present at the 42(nd) Annual J.P. Morgan Healthcare
Conference

 

Press release

 

TURKU, FINLAND / BOSTON, MA - January 3, 2024 - Faron Pharmaceuticals Oy (AIM:
FARN, First North: FARON), a clinical stage biopharmaceutical company pursuing
a CLEVER approach to reprogramming myeloid cells to activate immunity in
hematological and solid tumor microenvironments, today announces that Dr.
Markku Jalkanen, Chief Executive Officer, will present at the 42nd Annual J.P.
Morgan Healthcare Conference on Thursday January 11, 2024, at 12pm PT, in San
Francisco.

 

The presentation will be accessible through the "Investors" section of the
Company's website at www.faron.com (http://www.faron.com) and will be
available following the event.

 

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments treatments and as a monotherapy in last line solid
cancers. Further information is available at www.faron.com.

 

For more information please contact:

 

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com (mailto:daniel@lifesciadvisors.com)

+1 (617) 430-7576

 

ICR Consilium

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: Faron@consilium-comms.com (mailto:Faron@consilium-comms.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADLLFBZFLXBBZ